Replies to post #116647 on Biotech Values

[dewophile]

this was pretty much expected given the retail Rx share SNY gave at their last cc, but still nice to see it in the raw hard data

PS: by my calculation 71% of the retail market at 15% price discount to branded should generate about 170M a quarter in sales adding 20% of the hospital market - which seems well within reach - adds another 70M, so i stand by my projected 240M/quarter once steady state of inventory is reached

[redfairway]

MNTA::
Just on Kramer: Caller#1: What do you think of MNTA? Ans:Not familiar with the company.
Caller #2: What do you think of TEVA: Ans: Sell,disappointing results and potential threats to Copaxone franchise. LOL